Skip to main content
Premium Trial:

Request an Annual Quote

Qlucore, Genomax Ink Software Distribution Agreement

NEWYORK (GenomeWeb) – Qlucore has tapped Genomax Technologies to distribute its Omics Explorer software to biotechnology customers in Malaysia.

The agreement is intended to provide the Malaysian biotech market with easy access to Qlucore software, which offers workflows and tools for analyzing and exploring genomics data. According to Qlucore, growing numbers of researchers in the country are starting to use next-generation sequencing technologies in their research projects.

Genomax provides products and services that support life science research communities and medical institutions in Malaysia and has experience in the bioinformatics domain, which is why Qlucore is partnering with the company to distribute its software, according to Carl-Johan Ivarsson, Qlucore's president.

"We are confident that this cooperation will help researchers in Malaysia to learn more about our software, and to achieve extraordinary results with their data analysis," he said in a statement.

Financial and other terms of the agreement were not disclosed.  

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.